A Case of Dasatinib-Induced Keratosis Pilaris
Main Article Content
Keywords
keratosis pilaris, drug reaction, CML
Abstract
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.
References
2. Drucker AM, Wu S, Busam KJ, Berman E, Amitay-Laish I, Lacouture ME. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: Meta-analysis and clinical characterization. Eur J Haematol. 2013;90(2):142-150. doi:10.1111/ejh.12052
3. Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: Second-line drugs of choice. Am J Hematol. 2016;91(1):67-75. doi:10.1002/ajh.24247
4. Cortes JE, Jones D, O’Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28(3):389-404. doi:10.1200/JCO.2009.25.4920
5. Patel AB, Solomon AR, Mauro MJ, Ehst BD. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Dermatology. 2016;232(1):122-125. doi:10.1159/000437383
6. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24(4):386-395. doi:10.1111/j.1529-8019.2011.01431.x
7. Huang X, Patel S, Ahmed N, Seiter K, Liu D. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: Case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther. 2008;(2):215-219. doi:10.2147/dddt.s3843
8. Tarantini F, Anelli L, Ingravallo G, et al. Skin lesions in chronic myeloid leukemia patients during dasatinib treatment. Cancer Manag Res. 2019;11:7991-7996. doi:10.2147/CMAR.S217872
9. Bergman JC, Ly TY, Keating MM, Hull PR. Recurrent and fixed neutrophilic dermatosis associated with dasatinib. J Cutan Med Surg. 2018;22(6):621-623. doi:10.1177/1203475418775663
10. Lin YC, Wu MH, Wei TT, et al. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia (United States). 2012;14(6):463-475. doi:10.1596/neo.12300
11. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708-720. doi:10.1016/j.jaad.2013.06.038
12. Chen Z, Oh D, Dubey AK, et al. EGFR family and Src family kinase interactions: mechanics matters? Curr Opin Cell Biol. 2018;51:97-102. doi:10.1016/j.ceb.2017.12.003
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.